rs281864964
Variant summary
Our verdict is Pathogenic. The variant received 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_024312.5(GNPTAB):c.749dupA(p.Asn250LysfsTer5) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000062 in 1,613,594 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_024312.5 frameshift
Scores
Clinical Significance
Conservation
Publications
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 18 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| GNPTAB | NM_024312.5 | c.749dupA | p.Asn250LysfsTer5 | frameshift_variant | Exon 7 of 21 | ENST00000299314.12 | NP_077288.2 | |
| GNPTAB | XM_011538731.3 | c.668dupA | p.Asn223LysfsTer5 | frameshift_variant | Exon 7 of 21 | XP_011537033.1 | ||
| GNPTAB | XM_006719593.4 | c.749dupA | p.Asn250LysfsTer5 | frameshift_variant | Exon 7 of 19 | XP_006719656.1 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| GNPTAB | ENST00000299314.12 | c.749dupA | p.Asn250LysfsTer5 | frameshift_variant | Exon 7 of 21 | 1 | NM_024312.5 | ENSP00000299314.7 | ||
| GNPTAB | ENST00000549940.5 | c.749dupA | p.Asn250LysfsTer5 | frameshift_variant | Exon 7 of 11 | 1 | ENSP00000449150.1 | |||
| GNPTAB | ENST00000552681.1 | c.383dupA | p.Asn128LysfsTer5 | frameshift_variant | Exon 3 of 3 | 1 | ENSP00000449217.1 | |||
| RNA5SP368 | ENST00000364298.1 | n.*244_*245insT | downstream_gene_variant | 6 |
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152102Hom.: 0 Cov.: 32 show subpopulations
GnomAD2 exomes AF: 0.00000398 AC: 1AN: 251238 AF XY: 0.00 show subpopulations
GnomAD4 exome AF: 0.00000616 AC: 9AN: 1461492Hom.: 0 Cov.: 30 AF XY: 0.00000550 AC XY: 4AN XY: 727090 show subpopulations
Age Distribution
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152102Hom.: 0 Cov.: 32 AF XY: 0.0000135 AC XY: 1AN XY: 74292 show subpopulations
ClinVar
Submissions by phenotype
not provided Pathogenic:2
- -
Reported in a patient with GNPTAB-related mucolipidosis who also harbored an additional loss of function variant (PMID: 19634183); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25107912, 19617216, 30882951, 19634183) -
Pseudo-Hurler polydystrophy;C2673377:Mucolipidosis type II Pathogenic:1
This sequence change creates a premature translational stop signal (p.Asn250Lysfs*5) in the GNPTAB gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GNPTAB are known to be pathogenic (PMID: 19617216, 25107912). This variant is present in population databases (rs281864964, gnomAD 0.0009%). This premature translational stop signal has been observed in individual(s) with GNPTAB-related conditions (PMID: 19634183). ClinVar contains an entry for this variant (Variation ID: 39087). For these reasons, this variant has been classified as Pathogenic. -
Mucolipidosis Pathogenic:1
Variant summary: GNPTAB c.749dupA (p.Asn250LysfsX5) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 251438 control chromosomes. c.749dupA has been reported in the literature in compound heterozygosity with a known pathogenic variant in an individual affected with Mucolipidosis type II (Tappino_2009), providing evidence for pathogenicity. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One clinical diagnostic laboratory has submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation, classifying the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. -
Mucolipidosis type II Other:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at